SCHEMBL10028838

SCHEMBL10028838

Cc1ccc2c(c1)C(=O)c1cccc3c(C)ccc-2c13

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.76
SMN1; SMN2 Q16637 3/20 0.76
PABPC1 P11940 2/20 0.76
KDM4E B2RXH2 1/20 0.76
ELANE P08246 1/20 0.58
POLB P06746 1/20 0.47
MAOA P21397 1/20 0.46
MAOB P27338 1/20 0.46
TYMS P04818 1/20 0.43
CYP1A2 P05177 2/20 0.41
CYP3A4 P08684 2/20 0.41
DNMT1 P26358 1/20 0.41
CASP1 P29466 1/20 0.41
CASP7 P55210 1/20 0.41
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
HTT P42858 2/20 0.40
KEAP1 Q14145 2/20 0.40
NFE2L2 Q16236 2/20 0.40
NTRK1 P04629 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14985691 1.00 MAPT (0.76) MAPTSMN1; SMN2PABPC1KDM4EELANE
SCHEMBL18288098 0.86 SMN1; SMN2 (1.00) MAPTSMN1; SMN2PABPC1KDM4EELANE
SCHEMBL13006706 0.86 SMN1; SMN2 (1.00) MAPTSMN1; SMN2PABPC1KDM4EELANE
SCHEMBL12293691 0.82 MAPT (0.79) MAPTSMN1; SMN2PABPC1KDM4EELANE
SCHEMBL15500320 0.82 MAPT (0.68) MAPTSMN1; SMN2PABPC1KDM4EELANE
SCHEMBL18462559 0.82 MAPT (0.68) MAPTSMN1; SMN2PABPC1KDM4EELANE
SCHEMBL13924658 0.80 ELANE (0.65) MAPTSMN1; SMN2PABPC1KDM4EELANE
SCHEMBL22635004 0.78 PABPC1 (0.78) MAPTSMN1; SMN2PABPC1KDM4ETYMS
SCHEMBL354335 0.77 ELANE (0.95) MAPTSMN1; SMN2KDM4EELANEPOLB
SCHEMBL30419213 0.77 ELANE (0.95) MAPTSMN1; SMN2KDM4EELANEPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8541557-B2 Azo compound and method of preparing the azo compound RICOH COMPANY, LTD. (JP) 2013-09-24 US disclosed
US-20120253025-A1 AZO COMPOUND AND METHOD OF PREPARING THE AZO COMPOUND RICOH COMPANY, LTD. (JP) 2012-10-04 US disclosed
US-8232376-B2 Azo compound and method of preparing the azo compound RICOH COMPANY, LTD. (JP) 2012-07-31 US disclosed
US-8206880-B2 Electrophotographic photoreceptor, and image forming apparatus and process cartridge therefor using the photoreceptor RICOH COMPANY, LTD. (JP) 2012-06-26 US disclosed
US-8207312-B2 Method of preparing complex-AZO pigment and complex-AZO pigment thereof RICOH COMPANY, LTD. (JP) 2012-06-26 US disclosed
US-20100310975-A1 Electrophotographic Photoreceptor, And Image Forming Apparatus And Process Cartridge Therefor Using The Photoreceptor RICOH COMPANY, LTD. (JP) 2010-12-09 US disclosed
US-20100010204-A1 METHOD OF PREPARING COMPLEX-AZO PIGMENT AND COMPLEX-AZO PIGMENT THEREOF RICOH COMPANY, LTD. (JP) 2010-01-14 US disclosed
US-20090005546-A1 AZO COMPOUND AND METHOD OF PREPARING THE AZO COMPOUND RICOH COMPANY, LTD. (JP) 2009-01-01 US disclosed
US-7403735-B2 Image formation apparatus using an electrophotographic process RICOH COMPANY, LTD. (JP) 2008-07-22 US disclosed
US-7403735-B2 Image formation apparatus using an electrophotographic process RICOH COMPANY, LTD. (JP) 2008-07-22 US disclosed
US-7175958-B2 Electrophotographic photoconductor, process for forming an image, image forming apparatus and process cartridge for the same RICOH COMPANY, LTD. (JP) 2007-02-13 US disclosed
US-7175958-B2 Electrophotographic photoconductor, process for forming an image, image forming apparatus and process cartridge for the same RICOH COMPANY, LTD. (JP) 2007-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090005546-A1 AZO COMPOUND AND METHOD OF PREPARING THE AZO COMPOUND CRBN, REL, CDKL1 MAPT 3865/4885SMN1; SMN2 4742/4885PABPC1 4281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.